Comparing Scinai Immunotherapeutics (NASDAQ:SCNI) & Celularity (NASDAQ:CELU)

Celularity (NASDAQ:CELU) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares Celularity and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celularity	-246.65%	N/A	-48.20%
Scinai Immunotherapeutics	N/A	N/A	N/A

Volatility & Risk

Celularity has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500.

Earnings & Valuation

This table compares Celularity and Scinai Immunotherapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55 million	0.93	-$91.72 million	($1.69)	-0.45
Scinai Immunotherapeutics	$1.31 million	0.45	-$8.31 million	($95.34)	-0.00

Scinai Immunotherapeutics has lower revenue, but higher earnings than Celularity. Celularity is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

19.0% of Celularity shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 17.3% of Celularity shares are owned by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Celularity and Scinai Immunotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1	0	0	0	1.00
Scinai Immunotherapeutics	1	0	0	0	1.00

Summary

Scinai Immunotherapeutics beats Celularity on 7 of the 10 factors compared between the two stocks.

About Celularity

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.